<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855656</url>
  </required_header>
  <id_info>
    <org_study_id>RP-6306-01</org_study_id>
    <nct_id>NCT04855656</nct_id>
  </id_info>
  <brief_title>Study of RP-6306 in Advanced Solid Tumors</brief_title>
  <official_title>Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients With Advanced Solid Tumors (MYTHIC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repare Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repare Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and tolerability of RP-6306 in&#xD;
      patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and&#xD;
      assess preliminary anti-tumor activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, multi-center, open-label, dose-escalation study to:&#xD;
&#xD;
        -  Evaluate the safety profile and MTD of RP-6306 when administered orally to establish the&#xD;
           recommended Phase 2 dose and schedule&#xD;
&#xD;
        -  Characterize the PK and pharmacodynamics of RP-6306 monotherapy&#xD;
&#xD;
        -  Assess preliminary anti-tumor activity associated with RP-6306 monotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of RP-6306 in patients with advanced solid tumors as assessed by NCI CTCAE v5.0</measure>
    <time_frame>Up to 90 days after last administration of study intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To define the MTD of RP-6306 monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule</measure>
    <time_frame>Up to 90 days after last administration of study intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess PK parameters of RP-6306 monotherapy in fasted and fed states</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the relationship between pharmacodynamic biomarkers and PK of RP-6306 at different dose levels and/or schedules</measure>
    <time_frame>for the first 3 months on treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess preliminary anti-tumor activity of RP-6306 monotherapy</measure>
    <time_frame>Through Study Completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive RP-6306 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP-6306</intervention_name>
    <description>Oral PKMYT1 Inhibitor</description>
    <arm_group_label>Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female and ≥12 years-of-age at the time of informed consent.&#xD;
&#xD;
          -  Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1,&#xD;
             or 2 for patients &gt;16 years of age.&#xD;
&#xD;
          -  Locally advanced or metastatic resistant or refractory solid tumors.&#xD;
&#xD;
          -  Patients &lt;18 years of age must weigh at least 40 kg.&#xD;
&#xD;
          -  Submission of available tumor tissue at screening or willingness to have a biopsy&#xD;
             performed if safe and feasible&#xD;
&#xD;
          -  Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent&#xD;
             laboratory demonstrating eligible tumor biomarker.&#xD;
&#xD;
          -  Measurable disease as per RECIST v1.1.&#xD;
&#xD;
          -  Ability to swallow and retain oral medications.&#xD;
&#xD;
          -  Acceptable hematologic and organ function at screening.&#xD;
&#xD;
          -  Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at&#xD;
             Screening.&#xD;
&#xD;
          -  Resolution of all toxicities of prior therapy or surgical procedures.&#xD;
&#xD;
          -  Any prior radiation must have been completed at least 7 days prior to the start of&#xD;
             study drugs, and patients must have recovered from any acute adverse effects prior to&#xD;
             the start of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or small molecule antineoplastic agent given within 21 days or &lt;5&#xD;
             half-lives, whichever is shorter, prior to first dose of study drug.&#xD;
&#xD;
          -  History or current condition, therapy, or laboratory abnormality that might confound&#xD;
             the study results or interfere with the patient's participation for the full duration&#xD;
             of the study treatment.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Life-threatening illness, medical condition, active uncontrolled infection, or organ&#xD;
             system dysfunction or other reasons which, in the investigator's opinion, could&#xD;
             compromise the participating patient's safety.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to first dose of RP-6306.&#xD;
&#xD;
          -  Uncontrolled, symptomatic brain metastases.&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol and/or follow-up procedures outlined in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Manley, MD</last_name>
    <phone>857-322-5553</phone>
    <email>pmanley@reparerx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Participating site # 1002</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Participating Site # 1008</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Participating Site # 1004</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Participating Site # 1010</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Participating Site # 1001</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Participating Site #1013</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

